In another study of human colon cancer cell line xenograft, both the ATP competitive mTOR inhibitor PP242 and dual inhibitor of PI3K and mTOR NVP-BEZ235 significantly suppressed the xenograft growth, and they achieved better efficacy combined with a MEK inhibitor, implying a prosperous future for second generation mTOR inhibitors in combination therapies for CRC [174]. This evidence concerns the gene MAP2K7 and colorectal carcinoma.